Background Metformin has been available since 1957. Over 50 years later, one can
legitimately question whether a clear definition of its “therapeutic concentrations” is …

Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global
epidemic. In order to achieve optimal glucose control, it is often necessary to rely on …

Metformin use is associated with reduced cancer mortality, but how metformin impacts
cancer outcomes is controversial. Although metformin can act on cells autonomously to …

Accumulating evidence shows that metformin is an insulin-sensitizing antidiabetic drug
widely used in the treatment of type 2 diabetes mellitus (T2DM), which can exert favorable …

Therapeutic response to metformin, a first‐line drug for type 2 diabetes (T2D), is highly
variable, in part likely due to genetic factors. To date, metformin pharmacogenetic studies …

Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin
resistance and progressively reduced insulin secretion, which leads to impaired glucose …

OBJECTIVE Sulfonylureas, the first available drugs for the management of type 2 diabetes,
remain widely prescribed today. However, there exists significant variability in glycemic …

Metformin, the most widely prescribed antidiabetic drug, requires transporters to enter
tissues involved in its pharmacologic action, including liver, kidney, and peripheral tissues …

Metformin is the first-line medication for treatment of type 2 diabetes and has been shown to
reduce heart damage and death. However, mechanisms by which metformin protects human …

Effective interventions and treatments for complex diseases have been implemented
globally, however, coverage in Africa has been comparatively lower due to lack of capacity …